Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non-small cell lung cancer (NSCLC) in Europe.
Adolescent
Adult
Aged
Antineoplastic Agents
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Crizotinib
/ therapeutic use
Cross-Sectional Studies
Europe
Female
Health Communication
Humans
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Pamphlets
Patient Education as Topic
Protein Kinase Inhibitors
/ therapeutic use
Surveys and Questionnaires
Young Adult
crizotinib
patient information brochure
risk minimization
survey
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
28
10
2019
revised:
13
01
2020
accepted:
15
01
2020
entrez:
2
4
2020
pubmed:
2
4
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
Crizotinib (XALKORI
Identifiants
pubmed: 32232958
doi: 10.1002/prp2.570
pmc: PMC7105834
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Crizotinib
53AH36668S
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00570Informations de copyright
© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Références
Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):705-15
pubmed: 23349095
PLoS One. 2018 Aug 27;13(8):e0202865
pubmed: 30148862
Drug Saf. 2017 Apr;40(4):333-341
pubmed: 28074423
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Drug Saf. 2018 Aug;41(8):797-806
pubmed: 29671224
Drug Saf. 2014 Jan;37(1):33-42
pubmed: 24357107